Cargando…

LightSNiP assay is a good strategy for pharmacogenetics test

Detalles Bibliográficos
Autores principales:	Cheli, Stefania, Pietrantonio, Filippo, Clementi, Emilio, Falvella, Felicia S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451335/ https://www.ncbi.nlm.nih.gov/pubmed/26082719 http://dx.doi.org/10.3389/fphar.2015.00114

Ejemplares similares

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

Pharmacogenetic Practice of Anticancer Drugs: Multiple Approaches for an Accurate and Comprehensive Genotyping
por: Montrasio, Cristina, et al.
Publicado: (2023)

SNI/SNI Digital-Baghdad neurosurgery educational series
por: Ismail, Mustafa, et al.
Publicado: (2022)

Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions
por: Böhm, Ruwen, et al.
Publicado: (2016)

Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China
por: Zhang, Chunyan, et al.
Publicado: (2021)

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
por: Chang, Chih-Jung, et al.
Publicado: (2020)

Pharmacogenetics in the Brazilian Population
por: Suarez-Kurtz, Guilherme
Publicado: (2010)

In this issue of SNI — June 2010
por: Ausman, James I
Publicado: (2010)

Clinical and genetic determinants of nevirapine plasma trough concentration
por: Giacomelli, Andrea, et al.
Publicado: (2018)

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States
por: Lemke, Lauren K., et al.
Publicado: (2023)

Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy
por: Giacomelli, Andrea, et al.
Publicado: (2018)

Pharmacogenetics – Challenges and Opportunities Ahead
por: Zanger, Ulrich M.
Publicado: (2010)

Pharmacogenetics in Primary Headache Disorders
por: Belyaeva, Irina I., et al.
Publicado: (2022)

Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations
por: Eum, Seenae, et al.
Publicado: (2016)

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
por: Martens, Forike K., et al.
Publicado: (2020)

Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review
por: Roberts, Bradley, et al.
Publicado: (2023)

What's new in SNI for May, 2010?
por: Ausman, James I
Publicado: (2010)

Relevance of G-quadruplex structures to pharmacogenetics
por: Cree, Simone L., et al.
Publicado: (2014)

Pharmacogenetics in Psychiatry: An Update on Clinical Usability
por: van Schaik, Ron H. N., et al.
Publicado: (2020)

Editorial: Insights in Pharmacogenetics and Pharmacogenomics: 2021
por: Agúndez, José A. G., et al.
Publicado: (2022)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
por: Limdi, Nita A.
Publicado: (2012)

Actionable Pharmacogenetic Variation in the Slovenian Genomic Database
por: Hočevar, Keli, et al.
Publicado: (2019)

Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis
por: Numata, Shusuke, et al.
Publicado: (2018)

Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma
por: Zhou, Lin, et al.
Publicado: (2022)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity
por: Stewart, Stefan, et al.
Publicado: (2023)

SNI digital: A new educational service
por: Ausman, James I., et al.
Publicado: (2023)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics
por: Chua, E. W., et al.
Publicado: (2012)

Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
por: Roco, Ángela, et al.
Publicado: (2014)

Editorial: The Potential of Machine Learning in Pharmacogenetics, Pharmacogenomics and Pharmacoepidemiology
por: Garcia-Agundez, Augusto, et al.
Publicado: (2022)

Ensuring equity: Pharmacogenetic implementation in rural and tribal communities
por: Leitch, Tianna M., et al.
Publicado: (2022)

Editorial: Brief research reports in pharmacogenetics and pharmacogenomics: 2022
por: Sessa, Francesco, et al.
Publicado: (2023)

Editorial: Editor’s feature: negative findings in pharmacogenetics and pharmacogenomics
por: Agúndez, José A. G., et al.
Publicado: (2023)

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC(®)) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics
por: Blazy, Christopher, et al.
Publicado: (2022)

Pharmacogenetic aspects of addictive behaviors
por: Hejazi, Nadia S.
Publicado: (2007)

Pharmacogenetics and outcome with antipsychotic drugs
por: Pouget, Jennie G., et al.
Publicado: (2014)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
por: Bignucolo, A., et al.
Publicado: (2023)

Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes
por: Philips, Santosh, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_01ffaj85c98vg5qfb4ml7a57b5